8-K: BioAtla Secures $22.5M in New Financing Agreements

BioAtla, Inc. has entered into two new financing agreements, a $7.5 million Pre-Paid Advance and a $15.0 million Standby Equity Purchase Agreement, to bolster its capital.

Summary

• BioAtla, Inc. (the Company) entered into Pre-Paid Advance Agreements (PPAs) with YA II PN, Ltd. (Yorkville), Anson Investments Master Fund LP, and Anson East Master Fund LP (collectively, the Investors) for a $7.5 million advance.
• The Pre-Paid Advance will be purchased by the Investors at 95% of the face amount, resulting in gross proceeds of approximately $7.13 million for the Company.
• The Pre-Paid Advance accrues interest at an annual rate of 4%, increasing to 18% upon an event of default, and is due on the 12-month anniversary of the closing date.
• The Pre-Paid Advance can be repaid in cash or converted into common stock (PPA Shares) at the Investor's option, with conversion prices based on a formula involving VWAP and a Floor Price.
• The Company also entered into a Standby Equity Purchase Agreement (SEPA) with Yorkville, granting the Company the right to sell up to $15.0 million of common stock (SEPA Shares) over 36 months.
• Sales under the SEPA are at the Company's option, with a purchase price equal to 97% of the lowest daily VWAP during a three-day pricing period, subject to a minimum acceptable price set by the Company.
• A commitment fee of $300,000 for the SEPA was satisfied by issuing 243,428 shares of common stock to Yorkville, based on a VWAP of $1.2324.
• Both agreements are subject to limitations, including that beneficial ownership by any investor and its affiliates will not exceed 4.99% of outstanding common stock.
• The total aggregate number of shares issuable under both agreements is limited to 19.99% of the outstanding common stock as of November 17, 2025 (the Exchange Cap), unless stockholder approval is obtained, which the Company has agreed to seek.
• The Company has agreed not to enter into certain 'Variable Rate Transactions' or incur new indebtedness/liens (with exceptions) while the Pre-Paid Advance is outstanding, and grants the PPA Investors a right of first refusal on Variable Rate Transactions for 12 months.

Sentiment

Score: 6

Explanation: The company successfully secured significant financing, which is positive for liquidity and operations. However, the terms involve potential dilution and specific conditions that could lead to cash repayments or increased interest, indicating some financial pressure and risk.

Positives

• Secured access to up to $22.5 million in capital, providing significant financial runway for operations and development.
• The Standby Equity Purchase Agreement offers the Company flexibility to draw capital as needed over a 36-month period, without a mandatory minimum draw or non-usage fee.
• The Pre-Paid Advance provides immediate capital with a fixed interest rate (4%) under normal conditions.

Negatives

• The financing agreements involve significant potential for dilution of existing shareholders due to the issuance of new common stock.
• The Pre-Paid Advance was purchased at a 5% discount to face value, reducing immediate gross proceeds to $7.13 million from $7.5 million.
• A 2.00% commitment fee ($300,000) for the SEPA was paid through the issuance of 243,428 shares of common stock, representing an immediate dilutive cost.
• The Pre-Paid Advance includes conditions (e.g., Floor Price Event, Registration Event, Exchange Cap Event) that could trigger mandatory monthly cash repayments, plus a 10% payment premium and accrued interest, potentially straining cash flow.
• Events of default under the Pre-Paid Advance can lead to an increased interest rate of 18% per annum and immediate repayment of the outstanding balance plus a 10% premium.

Risks

• Market price volatility of the common stock could significantly impact the number of shares issued upon conversion of the Pre-Paid Advance or sales under the SEPA, leading to greater dilution.
• Failure to maintain the common stock's daily VWAP above the 'Floor Price' for the Pre-Paid Advance could trigger mandatory cash repayments, potentially impacting liquidity.
• If the Company fails to keep the registration statement effective or encounters issues with share eligibility, it could trigger mandatory cash repayments under the Pre-Paid Advance.
• The 'Exchange Cap' limits the total shares issuable under the agreements to 19.99% of outstanding shares without stockholder approval, potentially restricting the full utilization of the financing if approval is not obtained.
• The Company's agreement not to enter into certain 'Variable Rate Transactions' or incur new indebtedness/liens (with exceptions) while the Pre-Paid Advance is outstanding could limit future financing flexibility and strategic options.

Future Outlook

The agreements provide BioAtla with access to up to $22.5 million in capital over the next 36 months, offering financial flexibility to support its ongoing operations and strategic initiatives. The Company plans to seek stockholder approval to issue shares in excess of the Exchange Cap, which could further enhance its ability to utilize the full commitment amount under the SEPA.

Management Comments

• The Company acknowledges and agrees that it is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated by this Agreement and the other Transaction Documents.

Industry Context

Biotechnology companies, particularly those in development stages without substantial product revenue, frequently rely on equity and debt financing to fund extensive research and development, clinical trials, and operational expenses. Structures like Pre-Paid Advances and Standby Equity Purchase Agreements are common tools for such companies to secure capital flexibly, often balancing the need for funding with potential shareholder dilution. These arrangements allow companies to tap into capital markets as needed, rather than through large, single-tranche offerings, which can be beneficial in volatile market conditions.

Comparison to Industry Standards

• The financing structures, including the Pre-Paid Advance and Standby Equity Purchase Agreement, are typical for small to mid-cap biotechnology companies listed on Nasdaq, which often seek flexible capital solutions to fund R&D and operations.
• The discount rates (5% for the PPA face amount, 3% for SEPA purchase price) and interest rates (4% for PPA, 18% on default) are within the general range observed for similar financing arrangements in the biotech sector, reflecting the inherent risks associated with development-stage companies.
• The 4.99% beneficial ownership limitation for investors is a standard provision designed to prevent triggering certain SEC reporting requirements (e.g., Schedule 13D/G filings) and avoid potential 'control' implications for the investors.
• The 19.99% Exchange Cap, which limits the total shares issuable without shareholder approval, is a common Nasdaq listing rule that companies must navigate when raising capital through equity issuances.

Corporate Governance

Related Party Transactions

• Proceeds from the Pre-Paid Advance and SEPA cannot be used to repay advances or loans to any executives, directors, or employees of the Company or any Subsidiary, or to make any payments in respect of any related party obligations.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from the conversion of the Pre-Paid Advance and sales under the SEPA. Shareholder approval is required for issuances exceeding the 19.99% Exchange Cap, providing a mechanism for oversight.
• **Company (Liquidity)**: Enhanced liquidity and access to capital for operations and research and development over the next 36 months, supporting strategic objectives.
• **Creditors (PPA Investors)**: Secured a 4% interest-bearing advance with potential for an 18% interest rate on default and a 10% payment premium, providing a structured return or equity conversion option.

Next Steps

• The closing of the Pre-Paid Advance is expected to occur on or about November 21, 2025.
• The Company will file a current report on Form 8-K and a prospectus supplement related to these transactions.
• The Company has agreed to seek stockholder approval for the issuance of shares under the agreements in excess of the 19.99% Exchange Cap.
• The Company will maintain the effectiveness of the registration statement for the shares and comply with ongoing reporting and listing obligations.

Key Dates

Recommendation

The financing provides necessary capital, which is a positive for the company's operational runway. However, the terms involve significant potential dilution for existing shareholders and restrictions on future financing activities. The market's reaction to such agreements often balances the need for capital against the dilutive impact. A 'hold' recommendation reflects the mixed implications: while the company has secured funding, the cost of that funding and its potential impact on per-share value warrant caution rather than an immediate buy or sell. Investors should monitor the company's use of proceeds and progress on its pipeline.

Keywords

BioAtla, BCAB, financing, equity, debt, Pre-Paid Advance, Standby Equity Purchase Agreement, capital raise, Nasdaq, biotech, dilution